Perspective Therapeutics Files Q3 10-Q, Cites Key Agreements
Ticker: CATX · Form: 10-Q · Filed: Nov 12, 2024 · CIK: 728387
Sentiment: neutral
Topics: 10-Q, medical-devices, partnerships
TL;DR
Perspective Therapeutics (fka Isoray) Q3 10-Q filed. Mentions Viewpoint, Lantheus deals. Watch for updates.
AI Summary
Perspective Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as Isoray, Inc., is in the surgical and medical instruments sector. Key events mentioned include agreements with Viewpoint Molecular Targeting Inc. and Lantheus, and a name change from Isoray, Inc. in 2018.
Why It Matters
This filing provides insight into Perspective Therapeutics' financial health and strategic partnerships during the third quarter of 2024, which could impact its future growth and stock performance.
Risk Assessment
Risk Level: medium — The company has undergone name changes and is in a specific medical device sector, which can carry inherent risks.
Key Numbers
- 20240930 — Reporting Period End (Indicates the end of the fiscal quarter for which financial data is reported.)
- 20241112 — Filing Date (The date the 10-Q report was officially submitted to the SEC.)
Key Players & Entities
- Perspective Therapeutics, Inc. (company) — Filer
- Isoray, Inc. (company) — Former company name
- Viewpoint Molecular Targeting Inc. (company) — Partnered company
- Lantheus (company) — Partnered company
- 20240930 (date) — Reporting period end date
- 20241112 (date) — Filing date
FAQ
What is the primary business of Perspective Therapeutics, Inc.?
Perspective Therapeutics, Inc. is in the business of Surgical & Medical Instruments & Apparatus, as indicated by its SIC code 3841.
When was the company formerly known as Isoray, Inc.?
The company was formerly known as Isoray, Inc. until a name change on December 31, 2018.
What are some key agreements or partnerships mentioned in the filing data?
The filing data mentions agreements with Viewpoint Molecular Targeting Inc. and Lantheus, including investment and option agreements.
What is the fiscal year end for Perspective Therapeutics?
The fiscal year end for Perspective Therapeutics is December 31.
What is the SEC file number for Perspective Therapeutics?
The SEC file number for Perspective Therapeutics is 001-33407.
Filing Stats: 4,431 words · 18 min read · ~15 pages · Grade level 18 · Accepted 2024-11-12 16:11:58
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value CATX NYSE American LLC
Filing Documents
- catx-20240930.htm (10-Q) — 1733KB
- catx-ex10_1.htm (EX-10.1) — 173KB
- catx-ex31_1.htm (EX-31.1) — 15KB
- catx-ex31_2.htm (EX-31.2) — 15KB
- catx-ex32.htm (EX-32) — 10KB
- img49486978_0.jpg (GRAPHIC) — 9KB
- 0000950170-24-125399.txt ( ) — 8132KB
- catx-20240930.xsd (EX-101.SCH) — 1348KB
- catx-20240930_htm.xml (XML) — 1178KB
Financial Statements
Financial Statements 1 Condensed Consolidated Balance Sheets as of September 30, 2024 (unaudited) and December 31, 2023 1 Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2024 and 2023 (unaudited) 2 Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2024 and 2023 (unaudited) 3 Condensed Consolidated Statements of Changes in Stockholders' Equity for the three and nine months ended September 30, 2024 and 2023 (unaudited) 4 Notes to the Unaudited Condensed Consolidated Financial Statements 5 Item 2
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 18 Item 3
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 29 Item 4
Controls and Procedures
Controls and Procedures 29 PART II OTHER INFORMATION Item 1
Legal Proceedings
Legal Proceedings 30 Item 1A
Risk Factors
Risk Factors 30 Item 2 Unregistered Sales of Equity Securities and Use of Proceeds 30 Item 3 Defaults Upon Senior Securities 30 Item 4 Mine Safety Disclosures 30 Item 5 Other Information 31 Item 6 Exhibits 32
Signatures
Signatures 33 iii Table of Contents
- FINA NCIAL INFORMATION
PART I - FINA NCIAL INFORMATION
- FIN ANCIAL STATEMENTS
ITEM 1 - FIN ANCIAL STATEMENTS Perspective Therapeutics, Inc. and Subsidiaries Condensed Consolid ated Balance Sheets (In thousands, except shares and par value data) September 30, December 31, 2024 2023 (unaudited) ASSETS Current assets: Cash and cash equivalents $ 226,443 $ 9,238 Short-term investments 41,404 - Accounts receivable, net of allowance for doubtful accounts: 2024 - $ 592 ; 2023 - $ 650 217 1,165 Prepaid expenses and other current assets 2,108 1,133 Current assets held for sale, discontinued operations - 5,301 Total current assets 270,172 16,837 Noncurrent assets: Property and equipment, net 43,792 5,576 Right-of-use asset, net 2,433 747 Restricted cash - 182 Intangible assets, in-process research and development 50,000 50,000 Goodwill 24,062 24,062 Other assets, net 694 487 Total assets $ 391,153 $ 97,891 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable and accrued expenses $ 21,813 $ 6,909 Lease liability 903 46 Accrued personnel expenses 3,976 3,588 Note payable 51 49 Deferred Income (Note 3) 1,400 - Current liabilities of discontinued operations - 5,072 Total current liabilities 28,143 15,664 Noncurrent liabilities: Lease liability, net of current portion 1,676 780 Note payable, net of current portion 1,638 1,676 Deferred Income, net of current portion (Note 3) 26,600 - Deferred tax liability 4,592 4,592 Other noncurrent liabilities 33 - Total liabilities 62,682 22,712 Commitments and contingencies (Note 10) Stockholders' equity: Preferred stock, $ 0.001 par value; 7,000,000 shares authorized; 5,000,000 designated Series B convertible preferred stock; no shares issued and outstanding as of September 30, 2024 and December 31, 2023 - - Common stock, $ 0.001 par value; 750,000,000 shares authorized; 67,562,781 and 28,180,